These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31897761)

  • 1. Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
    Hashimoto M; Shirakawa Y; Maeda N; Tanabe S; Noma K; Sakurama K; Katsui K; Nishizaki M; Fujiwara T
    Esophagus; 2020 Apr; 17(2):127-134. PubMed ID: 31897761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT)
    Sakai M; Sohda M; Saito H; Nakazawa N; Ubukata Y; Kuriyama K; Hara K; Sano A; Ogawa H; Yokobori T; Murata K; Noda SE; Ohno T; Shirabe K; Saeki H
    Anticancer Res; 2021 Apr; 41(4):2141-2145. PubMed ID: 33813425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
    Kato K; Machida R; Ito Y; Daiko H; Ozawa S; Ogata T; Hara H; Kojima T; Abe T; Bamba T; Watanabe M; Kawakubo H; Shibuya Y; Tsubosa Y; Takegawa N; Kajiwara T; Baba H; Ueno M; Takeuchi H; Nakamura K; Kitagawa Y;
    Lancet; 2024 Jul; 404(10447):55-66. PubMed ID: 38876133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
    World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short-term Results.
    Sugimura K; Miyata H; Tanaka K; Makino T; Takeno A; Shiraishi O; Motoori M; Yamasaki M; Kimura Y; Hirao M; Fujitani K; Yasuda T; Mori M; Eguchi H; Yano M; Doki Y
    Ann Surg; 2021 Dec; 274(6):e465-e472. PubMed ID: 33065643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).
    Terada M; Hara H; Daiko H; Mizusawa J; Kadota T; Hori K; Ogawa H; Ogata T; Sakanaka K; Sakamoto T; Kato K; Kitagawa Y
    Jpn J Clin Oncol; 2019 Dec; 49(11):1055-1060. PubMed ID: 31411696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.
    Nakajima M; Muroi H; Kikuchi M; Kubo T; Inoue N; Ihara K; Nakagawa M; Morita S; Nakamura T; Kojima K
    Gen Thorac Cardiovasc Surg; 2023 Oct; 71(10):584-590. PubMed ID: 37060435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
    Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma.
    Hirose T; Yamamoto S; Honma Y; Yokoyama K; Hirano H; Okita N; Shoji H; Iwasa S; Takashima A; Ishiyama K; Oguma J; Daiko H; Maeda S; Kato K
    Esophagus; 2024 Jul; 21(3):328-335. PubMed ID: 38467986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
    Sugase T; Sugimura K; Kanemura T; Takeoka T; Yamamoto M; Shinno N; Hara H; Omori T; Fujii Y; Mukai Y; Mikamori M; Hasegawa S; Haraguchi N; Akita H; Nishimura J; Wada H; Matsuda C; Yasui M; Miyata H
    Oncology; 2022; 100(12):655-665. PubMed ID: 36198297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive Chemoradiotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil for Advanced Cervical Esophageal Cancer: A Medium-Term Outcome.
    Okamoto H; Taniyama Y; Sato C; Fukutomi T; Ozawa Y; Ando R; Takahashi K; Akaishi R; Horie Y; Shinozaki Y; Unno M; Kamei T
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):495-499. PubMed ID: 35225461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
    Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
    Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
    Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy for patients with cervical esophageal cancer: a single-center retrospective study.
    Sakai M; Sohda M; Saito H; Kuriyama K; Yoshida T; Kumakura Y; Hara K; Yokobori T; Miyazaki T; Murata K; Noda SE; Nakano T; Kuwano H; Shirabe K
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1121-1126. PubMed ID: 30972455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.
    Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Nagai Y; Asami C; Kitagawa Y
    Br J Cancer; 2016 Nov; 115(11):1328-1334. PubMed ID: 27811857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute.
    Sato Y; Mori K; Atsumi S; Sakamoto K; Oya S; Okamoto A; Urabe M; Miwa Y; Yajima S; Yagi K; Nomura S; Yamashita H; Seto Y
    Esophagus; 2024 Oct; 21(4):514-522. PubMed ID: 38987434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
    Ohkura Y; Ueno M; Udagawa H
    World J Surg Oncol; 2019 Jul; 17(1):125. PubMed ID: 31315622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.